Opdivo plus Low-dose Yervoy combination reduces risk of progression or death by 42%
Bristol-Myers Squibb announced initial results from the pivotal Phase 3 study, CheckMate -227, evaluating the Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab, 1 mg/kg) combination in first-line advanced non-small cell lung cancer patients with high tumor mutational burden. April 16, 2018